$256.03
-5.54-2.12%
At close: Aug 6, 5:00 PM EST
Jazz Pharmaceuticals PLC
JAZZNASDAQ
Jazz Pharmaceuticals Earnings & Forecasts
Jazz Pharmaceuticals (JAZZ) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Jazz Pharmaceuticals Guidance
Jazz Pharmaceuticals (JAZZ) last issued guidance on August 3, 2026 for fiscal year 2026. The company guided revenue in the range of $4.60B - $4.75B for the period.
Compared to prior guidance, Jazz Pharmaceuticals raised its revenue forecast from a prior range of $4.25B - $4.50B.
Jazz Pharmaceuticals has issued 20 guidance updates between November 9, 2022 and August 3, 2026. During this period, the company raised its outlook 9 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $5.94 | $4.49 | $6.16 | $5.43 |
| Actual | $5.71 | $6.34 | $6.64 | $8.13 |
| Surprise | -3.87% | +41.2% | +7.79% | +49.7% |
| Revenue | ||||
| Estimate | $1.11B | $977.6M | $1.17B | $1.11B |
| Actual | $1.21B | $1.61B | $1.20B | $1.13B |
| Surprise | +9.06% | +64.6% | +2.21% | +1.89% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $6.18 | $6.03 | $5.06 |
| Revenue | |||
| Consensus | $1.15B | — | — |
